Conference Presentation Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Advances in the Management of Hematologic Diseases: Pipeline Drugs Become Clinical Reality

Release Date: June 23, 2009| Expiration Date: June 23, 2010
May 30, 2009, Orlando, FL

Lecture Overview

This on-demand Webcast is from a satellite symposium held in conjunction with the 45th Annual Meeting of the American Society of Clinical Oncology held on May 29-June 2, 2009, in Orlando, FL.

The Advances in the Management of Hematologic Diseases: Pipeline Drugs Become Clinical Reality symposium has been designed to provide participants with leading-edge information on the novel, targeted anticancer therapies that are being developed for patients with hematologic malignancies, highlighting the mechanisms of action and the most current clinical data with these agents. This symposium will detail several of the key advancements in the rational targeting of proteins/processes that are disrupted in cancer and benign hematologic disorders, such as thrombopoiesis, fusion genes, and cell-cycle progression.

This educational activity is directed toward medical oncologists, translational researchers (both MDs and PhDs), drug developers from academia and industry, and other persons interested in cancer drug development. Fellows, nurses, physician assistants, and pharmacists are also invited to participate.

Upon completion of this educational activity, you should be able to:

  • Define the rationale for and evaluate the clinical data with thrombopoietic agents in immune thrombocytopenic purpura
  • Describe signaling through intracellular pathways and assess the feasibility of JAK2 and Syk inhibitors as anticancer agents
  • Discuss the mechanisms of action and evaluate clinical data with the different agents targeting cyclin-dependent kinases and histone deacetylases
  • Evaluate the availability and feasibility of clinical trials employing novel targeted agents in B-cell malignancies

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View the Flash video presentations and slides.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

View the Activity
You will be asked to login
or create an account.

Educational Grants

An educational grant for this activity was provided by:


  1. Amgen